70 related articles for article (PubMed ID: 6138950)
1. Modulation of dopamine receptor binding by ascorbic acid.
Madras BK; Chan B
Adv Biochem Psychopharmacol; 1983; 37():275-87. PubMed ID: 6138950
[No Abstract] [Full Text] [Related]
2. Ascorbate injury and EDTA (or manganese) protection of D2-dopamine receptors.
Chan B; Seeman P; Davis A; Madras BK
Eur J Pharmacol; 1982 Jun; 81(1):111-6. PubMed ID: 6126367
[TBL] [Abstract][Full Text] [Related]
3. Ascorbic acid, redox cycling, lipid peroxidation, and the binding of dopamine receptor antagonists.
Heikkila RE; Manzino L
Ann N Y Acad Sci; 1987; 498():63-76. PubMed ID: 3476003
[No Abstract] [Full Text] [Related]
4. Solubilized dopamine/neuroleptic receptors (D2-type).
Madras BK; Davis A; Chan B; Seeman P
Prog Neuropsychopharmacol; 1981; 5(5-6):543-8. PubMed ID: 6122229
[No Abstract] [Full Text] [Related]
5. Effects of pH and ascorbic acid on 3H-spiperone and 3H-dihydroalprenolol binding in rat forebrain homogenates.
Bruinink A; Lichtensteiger W
J Recept Res; 1984; 4(1-6):127-39. PubMed ID: 6527352
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibitory effects of ascorbic acid on the binding of dopamine agonists and antagonists to neostriatal membrane preparations: correlations with behavioral effects.
Heikkila RE; Cabbat FS; Manzino L
Res Commun Chem Pathol Pharmacol; 1981 Dec; 34(3):409-21. PubMed ID: 7323442
[TBL] [Abstract][Full Text] [Related]
7. Are striatal [3H]spiperone radioreceptor assays indicative of multiple dopamine receptor interactions?
Clements-Jewery S; Robson PA
Neuropharmacology; 1981 Dec; 20(12B):1295-8. PubMed ID: 7322304
[No Abstract] [Full Text] [Related]
8. Dopamine receptor: from synaptic membranes to solubilization.
Laduron P
Adv Biochem Psychopharmacol; 1980; 24():81-7. PubMed ID: 6105808
[No Abstract] [Full Text] [Related]
9. Binding of [3H]-neuroleptics to dopamine receptors on rat cerebral membranes [proceedings].
Howlett DR; Nahorski SR
Br J Pharmacol; 1978 Mar; 62(3):396P. PubMed ID: 25103
[No Abstract] [Full Text] [Related]
10. Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists.
De Lean A; Kilpatrick BF; Caron MG
Mol Pharmacol; 1982 Sep; 22(2):290-7. PubMed ID: 7144730
[No Abstract] [Full Text] [Related]
11. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
[TBL] [Abstract][Full Text] [Related]
12. The pituitary dopamine receptor.
Labrie F; Di Paolo T; Raymond V; Ferland L; Beaulieu M
Adv Biochem Psychopharmacol; 1980; 23():217-27. PubMed ID: 6104906
[No Abstract] [Full Text] [Related]
13. Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites.
Wong DT; Threlkeld PG; Bymaster FP
Arzneimittelforschung; 1993 Apr; 43(4):409-12. PubMed ID: 7684223
[TBL] [Abstract][Full Text] [Related]
14. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of a complex subunit composition of a unitary dopamine receptor: effects of lesions and proteolytic enzymes on stereospecific binding.
Leysen JE; Gommeren W; Van Gompel P
Adv Biochem Psychopharmacol; 1983; 36():147-62. PubMed ID: 6858752
[No Abstract] [Full Text] [Related]
16. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum.
Zahniser NR; Molinoff PB
Mol Pharmacol; 1983 Mar; 23(2):303-9. PubMed ID: 6835199
[TBL] [Abstract][Full Text] [Related]
17. Factors regulating ligand binding to 5-hydroxytryptamine receptors in rat brain.
Segawa T; Nomura Y; Nishio H; Taguchi J; Fujita M
Adv Exp Med Biol; 1984; 175():115-25. PubMed ID: 6093448
[No Abstract] [Full Text] [Related]
18. [3H]Ro 22-1319 (piquindone) binds to the D2 dopaminergic receptor subtype in a sodium-dependent manner.
Nakajima T; Iwata K
Mol Pharmacol; 1984 Nov; 26(3):430-8. PubMed ID: 6149457
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition of succinic dehydrogenase by manganese and its reversal by chelating agents.
Seth PK; Husain R
Environ Physiol Biochem; 1974; 4(4):176-80. PubMed ID: 4218550
[No Abstract] [Full Text] [Related]
20. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
Bacopoulos NG
J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
